FFR(CT) provides high diagnostic accuracy and discrimination for the diagnosis of hemodynamically significant CAD with invasive FFR as the reference standard. When compared with anatomic testing by using coronary CTA, FFR(CT) led to a marked increase in specificity. (HeartFlowNXT-HeartFlow Analysis of Coronary Blood Flow Using Coronary CT Angiography [HFNXT]; NCT01757678).
SummaryBackgroundRemote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). We investigated whether remote ischaemic conditioning could reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months.MethodsWe did an international investigator-initiated, prospective, single-blind, randomised controlled trial (CONDI-2/ERIC-PPCI) at 33 centres across the UK, Denmark, Spain, and Serbia. Patients (age >18 years) with suspected STEMI and who were eligible for PPCI were randomly allocated (1:1, stratified by centre with a permuted block method) to receive standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5-min inflation and 5-min deflation of an automated cuff device) before PPCI. Investigators responsible for data collection and outcome assessment were masked to treatment allocation. The primary combined endpoint was cardiac death or hospitalisation for heart failure at 12 months in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02342522) and is completed.FindingsBetween Nov 6, 2013, and March 31, 2018, 5401 patients were randomly allocated to either the control group (n=2701) or the remote ischaemic conditioning group (n=2700). After exclusion of patients upon hospital arrival or loss to follow-up, 2569 patients in the control group and 2546 in the intervention group were included in the intention-to-treat analysis. At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart failure (the primary endpoint) were 220 (8·6%) patients in the control group and 239 (9·4%) in the remote ischaemic conditioning group (hazard ratio 1·10 [95% CI 0·91–1·32], p=0·32 for intervention versus control). No important unexpected adverse events or side effects of remote ischaemic conditioning were observed.InterpretationRemote ischaemic conditioning does not improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 12 months in patients with STEMI undergoing PPCI.FundingBritish Heart Foundation, University College London Hospitals/University College London Biomedical Research Centre, Danish Innovation Foundation, Novo Nordisk Foundation, TrygFonden.
Background-Distal embolization during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction may result in reduced myocardial perfusion, infarct extension, and impaired prognosis. Methods and Results-In a prospective randomized trial, we studied the effect of routine thrombectomy in 215 patients with ST-segment-elevation myocardial infarction lasting Ͻ12 hours undergoing primary PCI. Patients were randomized to thrombectomy pretreatment or standard PCI. The primary end point was myocardial salvage measured by sestamibi SPECT, calculated as the difference between area at risk and final infarct size determined after 30 days (percent
AimsCoronary plaque characteristics are associated with ischaemia. Differences in plaque
volumes and composition may explain the discordance between coronary stenosis severity
and ischaemia. We evaluated the association between coronary stenosis severity, plaque
characteristics, coronary computed tomography angiography (CTA)-derived fractional flow
reserve (FFRCT), and lesion-specific ischaemia identified by FFR in a
substudy of the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next
Steps).Methods and resultsCoronary CTA stenosis, plaque volumes, FFRCT, and FFR were assessed in 484
vessels from 254 patients. Stenosis >50% was considered obstructive. Plaque volumes
(non-calcified plaque [NCP], low-density NCP [LD-NCP], and calcified plaque [CP]) were
quantified using semi-automated software. Optimal thresholds of quantitative plaque
variables were defined by area under the receiver-operating characteristics curve (AUC)
analysis. Ischaemia was defined by FFR or FFRCT ≤0.80. Plaque volumes were
inversely related to FFR irrespective of stenosis severity. Relative risk (95%
confidence interval) for prediction of ischaemia for stenosis >50%, NCP ≥185
mm3, LD-NCP ≥30 mm3, CP ≥9 mm3, and FFRCT
≤0.80 were 5.0 (3.0–8.3), 3.7 (2.4–5.6), 4.6 (2.9–7.4), 1.4 (1.0–2.0), and 13.6
(8.4–21.9), respectively. Low-density NCP predicted ischaemia independent of other
plaque characteristics. Low-density NCP and FFRCT yielded diagnostic
improvement over stenosis assessment with AUCs increasing from 0.71 by stenosis >50%
to 0.79 and 0.90 when adding LD-NCP ≥30 mm3 and LD-NCP ≥30 mm3 +
FFRCT ≤0.80, respectively.ConclusionStenosis severity, plaque characteristics, and FFRCT predict lesion-specific
ischaemia. Plaque assessment and FFRCT provide improved discrimination of
ischaemia compared with stenosis assessment alone.
The present large pooled analysis of randomized trials suggests that thrombectomy (in particular manual thrombectomy) significantly improves the clinical outcome in patients with STEMI undergoing mechanical reperfusion and that its effect may be additional to that of IIb/IIIa-inhibitors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.